Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation

被引:29
作者
Nelson, Winnie W. [1 ]
Wang, Li [2 ]
Baser, Onur [3 ,4 ]
Damaraju, Chandrasekharrao V. [5 ]
Schein, Jeffrey R. [1 ]
机构
[1] Janssen Sci Affairs LLC, Hlth Econ & Outcomes Res HECOR, Raritan, NJ 08869 USA
[2] STATinMED Res, Plano, TX USA
[3] STATinMED Res, Ann Arbor, MI USA
[4] MEF Univ, Istanbul, Turkey
[5] Janssen Res & Dev LLC, Raritan, NJ USA
关键词
Atrial fibrillation; Clinical outcomes; International normalized ratio; USA; US veterans; Warfarin; RISK-FACTOR; ANTICOAGULATION CONTROL; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULANT; PREDICTING STROKE; INTENSITY; HOSPITALS; QUALITY;
D O I
10.1007/s11096-014-0038-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Although efficacious in stroke prevention in non-valvular atrial fibrillation, many warfarin patients are sub-optimally managed. Objective To evaluate the association of international normalized ratio control and clinical outcomes among new warfarin patients with non-valvular atrial fibrillation. Setting Adult non-valvular atrial fibrillation patients (a parts per thousand yen18 years) initiating warfarin treatment were selected from the US Veterans Health Administration dataset between 10/2007 and 9/2012. Method Valid international normalized ratio values were examined from the warfarin initiation date through the earlier of the first clinical outcome, end of warfarin exposure or death. Each patient contributed multiple in-range and out-of-range time periods. Main outcome measure The relative risk ratios of clinical outcomes associated with international normalized ratio control were estimated. Results 34,346 patients were included for analysis. During the warfarin exposure period, the incidence of events per 100 person-years was highest when patients had international normalized ratio < 2:13.66 for acute coronary syndrome; 10.30 for ischemic stroke; 2.93 for transient ischemic attack; 1.81 for systemic embolism; and 4.55 for major bleeding. Poisson regression confirmed that during periods with international normalized ratio < 2, patients were at increased risk of developing acute coronary syndrome (relative risk ratio: 7.9; 95 % confidence interval 6.9-9.1), ischemic stroke (relative risk ratio: 7.6; 95 % confidence interval 6.5-8.9), transient ischemic attack (relative risk ratio: 8.2; 95 % confidence interval 6.1-11.2), systemic embolism (relative risk ratio: 6.3; 95 % confidence interval 4.4-8.9) and major bleeding (relative risk ratio: 2.6; 95 % confidence interval 2.2-3.0). During time periods with international normalized ratio > 3, patients had significantly increased risk of major bleeding (relative risk ratio: 1.5; 95 % confidence interval 1.2-2.0). Conclusion In a Veterans Health Administration non-valvular atrial fibrillation population, exposure to out-of-range international normalized ratio values was associated with significantly increased risk of adverse clinical outcomes.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [21] Stroke prevention in non-valvular atrial fibrillation: Can warfarin do better?
    Apostolakis, Stavros
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2011, 106 (05) : 753 - 754
  • [22] Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation
    Pastori, Daniele
    Farcomeni, Alessio
    Saliola, Mirella
    Del Sole, Francesco
    Pignatelli, Pasquale
    Violi, Francesco
    Lip, Gregory Y. H.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2018, 54 : 34 - 39
  • [23] Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation
    Nelson, Winnie W.
    Song, Xue
    Coleman, Craig I.
    Thomson, Erin
    Smith, David M.
    Damaraju, C. V.
    Schein, Jeffrey R.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (12) : 2461 - 2469
  • [24] Comparative Effectiveness of Dabigatran and Rivaroxaban versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Bengtson, Lindsay
    Chen, Lin
    MacLehose, Richard
    Lutsey, Pamela
    Alonso, Alvaro
    CIRCULATION, 2014, 130
  • [25] Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
    Kocis P.T.
    Liu G.
    Makenbaeva D.
    Trocio J.
    Velott D.
    Trainer J.A.B.
    Abdulsattar Y.
    Molina M.I.
    Leslie D.L.
    Drugs - Real World Outcomes, 2016, 3 (2) : 165 - 173
  • [26] Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure
    Martinez, Brandon K.
    Bunz, Thomas J.
    Eriksson, Daniel
    Meinecke, Anna-Katharina
    Sood, Nitesh A.
    Coleman, Craig I.
    ESC HEART FAILURE, 2019, 6 (01): : 10 - 15
  • [27] Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation
    Nakamura, Asako
    Kuroda, Junya
    Ago, Tetsuro
    Hata, Jun
    Matsuo, Ryu
    Arakawa, Shuji
    Kuwashiro, Takahiro
    Yasaka, Masahiro
    Okada, Yasushi
    Kitazono, Takanari
    Kamouchi, Masahiro
    CEREBROVASCULAR DISEASES, 2016, 42 (3-4) : 196 - 204
  • [28] International normalised ratio stability in patients aged 80 years and over taking warfarin for non-valvular atrial fibrillation
    Porter, A.
    Kennard, D.
    Lang, S. -J.
    Levy, S.
    Wang, Q.
    Chua, E.
    EUROPEAN GERIATRIC MEDICINE, 2016, 7 (05) : 411 - 415
  • [29] Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US
    Schoof, Nils
    Schnee, Janet
    Schneider, Gary
    Gawlik, Melissa
    Zint, Kristina
    Clemens, Andreas
    Bartels, Dorothee B.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (05) : 795 - 804
  • [30] An observational study of international normalized ratio control according to NICE criteria in patients with non-valvular atrial fibrillation: the SAIL Warfarin Out of Range Descriptors Study (SWORDS)
    Harris, Daniel E.
    Thayer, Daniel
    Wang, Ting
    Brooks, Caroline
    Murley, Geoff
    Gravenor, Mike
    Hill, Nathan R.
    Lister, Steven
    Halcox, Julian
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (01) : 40 - 49